WHAT IS CA 19-9 (CARBOHYDRATE ANTIGEN 19-9, GICA, GASTROINTESTINAL CANCER ANTIGEN) TEST?

WHAT IS CA 19-9 (CARBOHYDRATE ANTIGEN 19-9, GICA, GASTROINTESTINAL CANCER ANTIGEN) TEST?

The MUC1 gene is a high-molecular-weight glycoprotein found in specific tissues throughout the body (see Mucin-like carcinoma-associated antigen—Blood). The MUC1 gene has many varieties of carbohydrate chains that are termed mucin-like antigens, and one of these is the carbohydrate antigen 19-9 (CA 19-9) that circulates in the bloodstream when cancer is present. CA 19-9 is a glycoprotein present on a wide variety of adenocarcinomas of the gastrointestinal and hepatobiliary systems. CA 19-9 is produced in excess by the adenocarcinomas and released into the blood, enabling measurement. CA 19-9 is considered the standard of comparison often used marker for pancreatic cancer, along with CT, to differentiate from benign pancreatic disease. A total of 70%-80% of pancreatic cancers, 60% of hepatobiliary cancers, and 50%-60% of gastric carcinomas have elevated CA 19-9 levels. In pancreatic adenocarcinoma, 96% of tumours with CA 19-9 levels >1000 U/mL are considered unresectable. Serial elevated postoperative CA 19-9 levels often predict relapse of pancreatic carcinoma before clinical or radiographic findings, but the CA 19-9 levels are not often monitored because of the paucity of effective treatment for relapsed pancreatic carcinoma. The CA 19-9 glycoprotein is not expressed in Lewis (a- b-) individuals (nonsecretors), who account for approximately 7% of the U.S. population and approximately 20% of the population of Japan, leading to the possibility of false-negative results when CA 19-9 levels are being obtained. Because of the lack of high sensitivity and specificity of CA 19-9, it has not previously been considered useful as a screening test for early pancreatic cancer. However, it is currently being studied in conjunction with endoscopic ultrasound as a possible method for early detection. Of note, CA 19-9 is measured using a double monoclonal immunoassay. 

 

KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X